CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV
By Contract Pharma Staff | 11.17.20
Will partner with CDMOs to increase manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022.
CureVac N.V., a biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production and required technology transfers are underway.
The company plans to build a broad and integrated European vaccine manufacturing network with CDMO partners for each of the key manufacturing steps for CVnCoV. The company is expecting to significantly increase its existing manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022, while managing potential supply chain risks. An additional large-scale production facility supported by the European Investment Bank (EIB) at CureVac´s headquarters in Tübingen is currently in development.
“It is our goal to ramp up the production capacity of our vaccine candidate within a short period of time to ensure a stable supply,” said Dr. Florian von der Mülbe, Chief Production Officer of CureVac. “We are currently working with experienced CDMOs across Europe to establish a solid production network. Geographic proximity is an important factor for facilitating alignment and technology transfers.”
Over the coming weeks, CureVac expects to announce key CDMO and supplier partnerships. CureVac’s CVnCoV manufacturing network will leverage expertise and capacity across Germany, France, the Netherlands, Belgium, Spain and Austria, as well as potentially Sweden, Poland, Italy and Ireland.